close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Cognito Therapeutics

News headline image
Cognito Therapeutics Announces Presentation of New CSF Proteomic and EEG Biomarker Data for Spectris™ in Alzheimer’s Disease at CTAD 2025
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics to Present New Biomarker Data for Spectris™ in Alzheimer’s Disease at CTAD 2025
From Cognito Therapeutics
Via Business Wire
News headline image
WVU Rockefeller Neuroscience Institute and Cognito Therapeutics Launch Brain Health Collaboratory to Accelerate Neurotherapies with AI-powered Research
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Presents Clinical Trial Data Highlighting Neuroprotective Potential of Spectris™ in Alzheimer’s Disease at AAIC 2025
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics to Present Five Abstracts at AAIC 2025 Highlighting Spectris™ Treatment in Alzheimer’s Disease
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Completes Enrollment in HOPE Pivotal Study of Spectris™ AD Therapy for the Treatment of Patients with Alzheimer’s Disease
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announces Non-invasive Neuromodulation Therapy Delays Alzheimer’s Disease Progression
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announces Spectris™ Data Demonstrating Brain Structural Maintenance and Mechanism of Action in Alzheimer’s Disease at AD/PD™ 2025
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics to Present New Data on Spectris’™ Impact on Brain Structure in Alzheimer’s Disease at AD/PD 2025
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Strengthens Executive Team to Drive Next Phase of Growth and Commercialization
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announces Spectris™ Treatment Demonstrates Myelin and Synaptic Biomarker Changes in Alzheimer’s Disease
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Presents Early-Stage Cost-Effectiveness Analysis of Spectris™ Therapy in Alzheimer’s Disease at ISPOR 2024
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announces Spectris™ Treatment Demonstrates 56.4% Reduction in Alzheimer’s Disease Dependence Score with Strong Safety Profile
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Publishes Study Demonstrating Structural Brain Preservation in Alzheimer’s Disease in Frontiers in Neurology
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics to Present New Data for Spectris™ in Alzheimer’s Disease at CTAD 2024
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Appoints Christian Howell as Chief Executive Officer
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announce OVERTURE I Study Demonstrated Significant Time Savings Using Composite Measures of Function and Cognition
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announces Scientific Presentations at the Alzheimer’s Association International Conference 2024
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announces Presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024 Meeting
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announces Spectris™ Demonstrates Durable Effects on Activities of Daily Living in the OVERTURE II Study
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announces Oral Presentation at 2024 American Academy of Neurology (AAN) Annual Meeting
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announces Spectris™ OVERTURE OLE Study Data Supports Potential Disease Modification and Early Treatment in Alzheimer’s Disease
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics OVERTURE Clinical Trial in Alzheimer's Disease Published in Frontiers in Neurology
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announces Oral Presentation on Spectris Therapy Open-Label Study Data in Alzheimer’s Disease at AD/PD 2024
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Announces First Patient Enrolled in HOPE Biomarker Study
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Phase 2 OVERTURE Study MRI Imaging Analysis Published in Journal of Alzheimer’s Disease
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics to Present at the 35th Annual Piper Sandler Healthcare Conference
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Appoints Christian Howell as Chief Commercial Officer
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics Presents Phase 2 OVERTURE Study Open-Label Extension Data Showing Safety, Adherence and Durability of Treatment Benefits Over 18 Months
From Cognito Therapeutics
Via Business Wire
News headline image
Cognito Therapeutics to Present Phase 2 OVERTURE Study Open-Label Extension Data Showing Safety and Durability of Treatment Benefits Over 18 Months at CTAD 2023
From Cognito Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today